To Help Blood Cells Regenerate After Radiotherapy, "Mechanoprime" MSCs

Radiation therapy to the bone marrow destroys cancerous leukemia and lymphoma cells, but it also leaves patients susceptible to infection until their blood cells can regenerate. Researchers at the Massachusetts Institute of Technology (MIT) have found a way to speed up this regeneration by using a technique known as "mechanopriming" to enhance the ability of mesenchymal stromal cells (MSCs) to aid in the process. Mesenchymal stromal cells are stem cells capable of differentiating into a variety ...
Continue reading

New Target Identified in Deadly Leukemia

Researchers at The University of Texas Southwestern (UT Southwestern) and The University of Texas Health Science Center at Houston have uncovered a possible new target for treating acute myeloid leukemia (AML), a subtype of blood and bone marrow cancer. Annually, 20,000 new cases of AML are diagnosed and over 10,000 people die of the disease in the US alone, according to statistics provided by the National Cancer Institute. "AML is a terrible disease. The five-year survival rate is 27% in the US...
Continue reading

Duvelisib Approved for Non-Hodgkin Lymphoma Subtypes

The FDA has now granted regular approval to duvelisib (Copiktra®, Verastem, Inc.) as a third-line or later treatment for adults with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). The FDA has also granted duvelisib accelerated approval as a third-line or later treatment for adults with relapsed or refractory follicular lymphoma (FL). Both CLL/SLL and FL are slow-growing types of non-Hodgkin lymphoma characterized by high rates of relapse, with limited...
Continue reading

Software Identifies Potential Immunotherapy Targets in Acute Myeloid Leukemia

A new study published in Blood Advances presents findings that may assist in the development of immune-based treatments tailored specifically for patients with acute myeloid leukemia (AML) undergoing allogeneic stem cell transplantation (ASCT). The genetic signatures present in a patient's cells produce proteins that are distinct from the proteins produced in donor cells. By analyzing these proteins, researchers at the University of North Carolina-Chapel Hill were able to observe how a donor's n...
Continue reading

Acute Lymphoblastic Leukemia: Immune Differences at Birth

In a new study published in Cancer Research , investigators have found neonatal inflammatory markers associated with childhood B-cell precursor acute lymphoblastic leukemia (ALL), indicating that children with ALL are born with a dysregulated immune function that may cause abnormal reactions to early childhood infections. "Our findings suggest that children who develop ALL are immunologically disparate already at birth," stated lead author Signe Holst Søegaard, MSc, a PhD student in the Departme...
Continue reading

© Copyright 2019 i3 Health. All rights reserved.